Digital Diabetes Management Market Size & Share 2026-2035

Digital Diabetes Management Market Size

The global digital diabetes management market was valued at USD 20.2 billion in 2025 and is projected to reach USD 69.1 billion by 2035, expanding at a CAGR of 13.3% over 2026–2035. The market reaches USD 22.5 billion in 2026.

Digital diabetes management includes connected continuous glucose monitoring (CGM) systems, smart insulin delivery devices, smart blood glucose meters, telemedicine and remote-monitoring services, diabetes education and coaching, and software and apps that support data management, clinical decision-making, or patient self-management. It excludes conventional unconnected glucose monitoring and insulin-delivery products without a digital management function.

Growth reflects a shift from episodic clinical intervention toward continuous, data-enabled self-management. Device hardware accounts for 91.5% of 2025 revenue, yet software and apps expand at 19.0% CAGR, faster than the total market. The revenue mix therefore begins with device-led adoption but increasingly depends on data aggregation, predictive analytics, and recurring care services.

The estimate uses triangulation across connected-device adoption, care-delivery services, software-platform activity, patient-type demand, end-use settings, and regional uptake. The 2025 base estimate anchors the forecast, while the 2026–2035 model reflects the interaction of diabetes prevalence, reimbursement expansion, healthcare spending, product awareness, affordability, and interoperability constraints. The driver and restraint effects are directional rather than strictly additive.

Key Drivers

Rising Number of People Suffering From Diabetes

The diabetes burden remains the largest structural demand driver. Approximately 537 million adults lived with diabetes globally in 2021, and the International Diabetes Federation projects 783 million by 2045. ^{[1]International Diabetes Federation, "Diabetes Atlas," idf.org} Aging populations, sedentary urban lifestyles, and obesity enlarge the patient pool more quickly than conventional endocrinology capacity can expand. Connected monitoring and remote care therefore address a care-delivery constraint as well as an individual clinical need. The demand effect is acute in South and Southeast Asia and Sub-Saharan Africa, where specialist access is constrained. Broader patient populations increase demand for scalable self-management tools, not merely in-clinic devices.

Rising Healthcare Expenditure Toward Diabetes

Diabetes-related healthcare spending exceeds USD 966 billion annually across OECD economies. ^{[3]Organisation for Economic Co-operation and Development, "Health at a Glance," oecd.org} Governments and payers are shifting budget attention toward prevention, remote monitoring, and digital therapeutics to reduce avoidable complication and hospitalization costs. This changes the addressable market because payer coverage converts an individual purchase decision into institutional procurement and recurring reimbursement. Medicare and Medicaid programs in the US, NHS-linked pathways in the UK, and statutory insurance frameworks in Germany and France create distinct funding routes. The more consequential effect is that digital management becomes part of a long-term care model rather than a discretionary technology purchase.

Growing Awareness About Technologically Advanced Products

CGM, smart insulin delivery, and integrated platforms have gained clinical and consumer visibility through guidelines, education campaigns, and published outcome evidence. CGM-enabled care has demonstrated improved glycemic outcomes relative to conventional self-monitoring, including lower HbA1c levels and fewer hypoglycemic events. ^{[6]The Lancet, "Diabetes and Digital Health Research," thelancet.com} In the US, Germany, and Australia, awareness is less often the limiting factor than affordability and reimbursement. In lower-penetration markets, digital outreach and structured diabetes education widen the potential adopter pool. Product awareness matters commercially when patients understand how continuous data alters daily decisions, not simply when devices are recognized by name.

Favorable Reimbursement Policies

CMS extended CGM coverage to Medicare beneficiaries with insulin-requiring diabetes, removing a longstanding access restriction. ^{[4]Centers for Medicare & Medicaid Services, "Remote Physiologic Monitoring," cms.gov} Germany and France have also expanded reimbursement routes for CGM systems and connected insulin pens. Reimbursement lowers the initial financial barrier and supports repeat utilization of devices, supplies, software, and care services. The policy effect is strongest in markets where coverage includes both monitoring technology and clinician review. It also gives manufacturers an incentive to demonstrate outcome value to payers rather than compete only on consumer features.

Key Restraints

High Cost of Advanced Devices

CGM systems, smart pumps, and integrated platforms retain acquisition and subscription costs that restrict access without insurance coverage. The constraint is pronounced in Latin America, the Middle East, Africa, and uninsured segments of developed markets. Reimbursement growth in North America and Western Europe has not eliminated the out-of-pocket challenge elsewhere. A bifurcated market follows: reimbursement-supported markets realize deeper penetration, while cost-sensitive markets remain below clinical demand potential. Tiered product architectures and subscriptions improve access at the margin, but they have not closed the gap at commercial scale. Cost pressure will remain a long-term restraint even as sensor and software economics improve.

Rising Number of Product Launches and Market Fragmentation

New CGM, smart-delivery, and software launches increase choice but also complicate clinical evaluation and procurement. Devices differ by connectivity protocol, analytics integration, and clinical validation. Data generated on one platform may not integrate cleanly with another platform, reducing utility in multi-device care environments. The resulting switching costs discourage organizations from replacing entrenched systems. FDA and European Commission digital-health guidance increasingly addresses software oversight and interoperability expectations. ^{[5]U.S. Food and Drug Administration, "Digital Health Center of Excellence," fda.gov} The market will favor vendors that make cross-device data usable without imposing a closed proprietary workflow.

Digital Diabetes Management Market Segment Analysis

By Product

Devices lead the market with 91.5% share and a 13.0% CAGR. Services account for 5.2% of 2025 revenue and expand at 13.4% CAGR, while software and apps account for 3.3% and grow at 19.0% CAGR. CGM systems are the dominant device modality at 53.4% of device-segment revenue and 13.3% CAGR. Abbott FreeStyle Libre 3, Dexcom G7, and Senseonics Eversense E3 represent flash sensing, real-time wireless monitoring, and implantable sensing architectures, respectively.

Smart insulin pumps and patches account for 28.7% of device revenue and grow at 12.9% CAGR. Medtronic MiniMed 780G, Tandem t:slim X2 with Control-IQ, and Insulet Omnipod 5 demonstrate the shift toward automated insulin delivery. Smart insulin pens account for 16.3% of device revenue and grow at 12.2% CAGR; NovoPen 6, NovoPen Echo Plus, Emperra ESYSTA, and Pendiq address dose documentation without requiring pump therapy. Smart blood glucose meters retain a 1.5% device-revenue share and 11.9% CAGR. Ascensia Contour Next One and Roche Accu-Chek Guide Me sustain relevance through Bluetooth connectivity and app integration. ^{[10]New England Journal of Medicine, "Automated Insulin Delivery Research," nejm.org}

Wearable devices account for 61.3% of device revenue and grow at 13.3% CAGR, compared with 38.7% and 12.5% CAGR for handheld devices. Abbott FreeStyle Libre 3 and Dexcom G7 illustrate miniaturized wearable monitoring, while FreeStyle Libre readers and Dexcom standalone receivers preserve a handheld option for patients who do not use smartphones. Wearables gain from continuous data capture, whereas handheld devices remain useful for elderly patients, point-of-care workflows, and regions with limited connectivity.

Services generate recurring revenue through telemedicine and virtual consultations, remote monitoring, and diabetes education, coaching, and support. Telemedicine holds 37.3% of services revenue and expands at 14.1% CAGR. Remote monitoring holds 33.4% and grows at 13.8% CAGR, supported by Glooko clinical dashboards and Medtronic CareLink portals. Education, coaching, and support account for 29.4% and grow at 12.1% CAGR; DarioHealth and Roche mySugr integrate coaching into the patient interface. CMS remote physiologic monitoring codes underpin clinical review and remote titration services. ^{[4]Centers for Medicare & Medicaid Services, "Remote Physiologic Monitoring," cms.gov}

Software and apps are the fastest-growing product category. Data management software and platforms hold 61.3% of segment revenue and grow at 67.8% CAGR, while digital diabetes management apps hold 38.7% and grow at 32.2% CAGR. Glooko aggregates data from more than 200 connected diabetes device types, and Tidepool provides an open-source data platform for CGM and insulin-delivery information. ^{[8]IEEE Spectrum, "Machine Learning and Continuous Glucose Monitoring," spectrum.ieee.org} Roche mySugr, Dexcom Clarity, Abbott LibreLink, and DarioHealth operate as patient-facing apps. Software-as-a-medical-device oversight is intensifying where applications make dosing recommendations. ^{[5]U.S. Food and Drug Administration, "Digital Health Center of Excellence," fda.gov}

By Patient Type

Type 2 diabetes represents 58.6% of market revenue and grows at 13.6% CAGR. Its larger population and broader expansion of CGM into non-insulin-dependent care make it the principal absolute-growth segment. Connected insulin pens such as NovoPen 6 and NovoPen Echo Plus provide a lower-complexity entry point for insulin-requiring type 2 patients. CGM also supports lifestyle feedback, dietary management, and earlier intervention in non-insulin type 2 care. Evidence and payer recognition will determine how widely that use case converts into reimbursed adoption. ^{[9]Diabetes Care, "Diabetes Technology Research," diabetesjournals.org}

Type 1 diabetes accounts for 41.4% of revenue and expands at 12.9% CAGR. Adoption is mature among type 1 adults in high-income markets, with usage rates above 70% among US adults under 65. ^{[7]National Institute of Diabetes and Digestive and Kidney Diseases, "Continuous Glucose Monitoring," niddk.nih.gov} Growth therefore centers on upgrades from standalone monitoring to integrated AID systems. MiniMed 780G, Omnipod 5, and t:slim X2 with Control-IQ serve the technology-intensive type 1 segment, while connected pens serve patients who continue multiple daily injections. The next upgrade cycle depends on integration quality, wearability, and payer coverage rather than initial device awareness.

By End Use

Hospitals hold 62.9% of market revenue and grow at 13.7% CAGR. Inpatient CGM, AID deployment in specialist units, and enterprise data-platform licensing drive institutional spending. FDA-cleared hospital-use indications support CGM integration into perioperative and critical-care protocols. Primary research conducted across procurement teams at 12 major US hospital systems in Q1 2026 indicates that CGM-based inpatient monitoring programs are being deployed or piloted widely, with data-platform integration emerging as the central implementation challenge. Hospital contracts increasingly link device deployments to population-health reporting and value-based care outcomes.

Home settings account for 20.4% of revenue and expand at 12.3% CAGR. Personal CGM, connected pens, smart delivery devices, and app subscriptions dominate this setting. Remote-monitoring reimbursement supports care continuity between visits, while wearable devices reduce the need for constant clinical supervision. Home use will gain revenue share as type 2 patients initiate technology-enabled care outside specialist facilities.

Diagnostic centers and clinics account for 11.9% of revenue and advance at 13.3% CAGR. Endocrinology practices, specialty clinics, primary-care diabetes programs, and diagnostic laboratories form a fragmented purchasing environment. Professional recommendations from the American Diabetes Association and European Association for the Study of Diabetes support CGM use for insulin-requiring outpatient populations. Other end users account for 4.8% of revenue and grow at 11.5% CAGR. Employer programs, research institutions, military health systems, and diabetes camps contribute modest direct revenue but generate evidence and validation that influence payer and provider adoption.

Digital Diabetes Management Market Regional Analysis

North America

North America leads with 33.4% of global revenue in 2025 and a 13.1% CAGR. The US is the primary contributor, supported by CGM penetration above 70% among type 1 adults under 65 and broad private-insurance and Medicare coverage. CMS expanded CGM coverage for insulin-requiring Medicare beneficiaries in 2023. Medtronic MiniMed 780G, Insulet Omnipod 5, and Tandem t:slim X2 with Control-IQ lead the premium AID tier. Canada is expanding provincial coverage, particularly in British Columbia and Ontario. The regional constraint is payer variation across private plans and provinces, which can delay uniform access.

Europe

Europe accounts for 28.8% of revenue and advances at 13.5% CAGR. Germany is the largest regional market, supported by statutory health insurance and the Digital Health Applications pathway for software-as-a-medical-device reimbursement. ^{[11]European Medicines Agency, "Medical Devices and Digital Health," ema.europa.eu} EU MDR 2017/745 reached full enforcement for legacy-exempt devices in May 2024, raising clinical-evidence and post-market surveillance requirements. France and the UK are extending CGM coverage for insulin-requiring type 2 patients, while the NHS Long Term Plan supports remote-monitoring pathways. Regulatory compliance remains a material entry barrier for smaller manufacturers.

Asia Pacific

Asia Pacific holds 21.1% of revenue and records the fastest regional CAGR at 13.7%. China and India provide the largest absolute patient pools and the highest growth opportunity. China’s Healthy China 2030 initiative includes digital health and chronic-disease self-management, while domestic suppliers Yuwell and Sinocare compete with Abbott and Dexcom in volume-sensitive CGM segments. India’s National Digital Health Mission, now the Ayushman Bharat Digital Mission, supports health identifiers and digital-record infrastructure. Japan emphasizes miniaturized sensors, and South Korea emphasizes AI-augmented analytics. The region’s constraint is uneven reimbursement and variable clinical infrastructure across countries.

Latin America

Latin America represents 9.3% of revenue and grows at 12.7% CAGR. Brazil is the regional leader and one of the highest near-term opportunity markets alongside China and India. Brazil’s SUS system is expanding digital monitoring capabilities, although CGM and AID reimbursement remains concentrated in high-clinical-need type 1 populations. ANVISA governs device and digital-health approval, and Abbott and Dexcom operate directly in Brazil and Mexico. Argentina, Colombia, and Chile remain more distribution dependent. Affordability limits penetration beyond privately insured upper-income groups.

Middle East and Africa

The Middle East and Africa account for 7.4% of revenue and grow at 12.7% CAGR. Saudi Arabia and the UAE have high diabetes prevalence, with IDF estimates above 17% in Saudi Arabia and 15% in the UAE. ^{[1]International Diabetes Federation, "Diabetes Atlas," idf.org} Saudi Arabia’s Vision 2030 and National Digital Health Strategy support telemedicine and chronic-disease management. UAE hospital networks, including SEHA and Dubai Health Authority facilities, have piloted structured digital monitoring programs. South Africa is the largest sub-Saharan commercial market, but adoption concentrates in the private-insurance population. Limited reimbursement and public-sector budgets remain the region’s central constraints.

Digital Diabetes Management Market Share & Competitive Landscape

Abbott Laboratories, Dexcom, Inc., Medtronic Plc, Insulet Corporation, and F. Hoffmann-La Roche Ltd collectively account for approximately 80% of market revenue. Concentration is highest in CGM and AID, where clinical validation, regulatory clearance, manufacturing scale, and clinical education form high barriers to entry. The remaining approximately 20% includes software-focused, connected-pen, implantable-CGM, and niche-device providers.

Abbott leads the flash glucose-monitoring tier through the FreeStyle Libre 2, FreeStyle Libre 3, and FreeStyle Libre 3 Plus families. Its competitive edge rests on broad payer contracting, direct-to-patient marketing, clinical education, and expansion across Asia Pacific and Latin America. Dexcom is a pure-play CGM leader; Dexcom G7 combines a smaller form factor and a 30-minute warm-up time, while Dexcom Clarity extends the device into patient and provider analytics. Medtronic combines MiniMed 780G, Guardian Sensor CGM, and CareLink into a clinically integrated pump and data-management portfolio.

Insulet differentiates through the tubeless Omnipod 5 platform, smartphone control, and compatibility with Dexcom G6 and G7. Roche participates through Accu-Chek devices and the mySugr platform, which combines logbook, coaching, and multi-device data functions. Tandem Diabetes Care competes through t:slim X2 with Control-IQ and software-updatable pump capability. Senseonics provides Eversense E3, an implantable CGM with up to 365-day wear and FDA clearance.

Major players operating in the digital diabetes management market include:

• Integrated device and care-platform leaders: Abbott Laboratories; Dexcom, Inc.; Medtronic Plc; Insulet Corporation; F. Hoffmann-La Roche Ltd.

• Connected-monitoring and smart-pen specialists: Ascensia Diabetes Care Holdings AG; Emperra GmbH E-Health Technologies; Novo Nordisk A/S; Pendiq; Ypsomed Holding.

• Software, data, and care-management specialists: DarioHealth Corporation; Glooko Inc.; Tidepool.

• Specialized sensing and AID providers: Senseonics; Tandem Diabetes Care, Inc.

Ascensia operates the Contour portfolio and associated digital tools, with European and Asian distribution strength. DarioHealth connects blood glucose monitoring, coaching, telehealth, and population-health analytics for employer and managed-care customers. Emperra’s ESYSTA supports automatic dose logging and telemedicine-linked care. Glooko aggregates data from more than 200 connected devices, supporting hospital systems, managed-care organizations, and research programs.

Novo Nordisk extends its insulin franchise with NovoPen 6, NovoPen Echo Plus, digital-health partnerships, and Cornerstones4Care. Pendiq targets multiple-daily-injection patients through dose tracking and reminders. Tidepool operates an open-source data-management platform and has submitted Tidepool Loop for FDA clearance. Ypsomed supplies smart pens, patch-pump systems, YpsoMate, and mylife YpsoPump through branded sales and business-to-business component relationships.

Key developments preserve the sector’s emphasis on interoperability, reimbursement, and software integration. Dexcom expanded G7 compatibility with additional AID systems across European markets in March 2025. CMS finalized expanded remote-patient-monitoring reimbursement rules in January 2025. Abbott received US clearance for FreeStyle Libre 3 Plus in November 2024. Insulet reported Omnipod 5 launches across major European markets in September 2024. Tandem received FDA clearance for an updated Control-IQ version in July 2024. 

Recent Industry Developments

• Mar 2025: Dexcom announced expanded compatibility of the G7 CGM platform with additional automated insulin delivery systems across European markets. The move expands the platform’s ecosystem relevance beyond the US.

• Jan 2025: CMS finalized expanded remote patient monitoring reimbursement rules under CPT code updates for certified digital diabetes management programs. The revised rules broaden the revenue basis for remote clinical review.